US Patent RE47885 Use of cannabidiol prodrugs in pharmaceutical compositions
Patent RE47885 was granted and assigned to Zynerba Pharmaceuticals on March, 2020 by the United States Patent and Trademark Office.
All edits
Described herein are cannabidiol prodrugs used in pharmaceutical compositions as well as microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer.
US Patent RE047885 Use of cannabidiol prodrugs in pharmaceutical compositions US Patent RE47885 Use of cannabidiol prodrugs in pharmaceutical compositions
US Patent RE047885 Use of cannabidiol prodrugs in pharmaceutical compositions
Find more entities like US Patent RE47885 Use of cannabidiol prodrugs in pharmaceutical compositions
